针对两大最常见致癌突变,最新研究发现“癌症之王”治疗新策略
Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis
作者:Michael P Kim, Xinqun Li, Jenying Deng, Yun Zhang, Bingbing Dai, Kendra L Allton, Tara G. Hughes, Christian Siangco, Jithesh J. Augustine, Ya'an Kang, Joy M McDaniel, Shunbin Xiong, Eugene J Koay, Florencia McAllister, Christopher A. Bristow, Timothy P. Heffernan, Anirban Maitra, Bin Liu, Michelle C. Barton, Amanda R Wasylishen, Jason B. Fleming, Guillermina Lozano
期刊:Cancer Discovery
发表时间:2021/03/26
摘要:
Pancreatic ductal adenocarcinoma (PDAC) is almost uniformly fatal and characterized by early metastasis. Oncogenic KRAS mutations prevail in 95% of PDAC tumors and co-occur with genetic alterations in the TP53 tumor suppressor in nearly 70% of patients. Most TP53 alterations are missense mutations that exhibit gain-of-function phenotypes that include increased invasiveness and metastasis yet the extent of direct cooperation between KRAS effectors and mutant p53 remains largely undefined. We show that oncogenic KRAS effectors activate cyclic AMP responsive element binding protein 1 (CREB1) to allow physical interactions with mutant p53 that hyperactivate multiple pro-metastatic transcriptional networks. Specifically, mutant p53 and CREB1 upregulate the pro-metastatic, pioneer transcription factor, FOXA1, activating its transcriptional network while promoting Wnt/B-catenin signaling, together driving PDAC metastasis. Pharmacologic CREB1 inhibition dramatically reduced FOXA1 and B-catenin expression and dampened PDAC metastasis, identifying a new therapeutic strategy to disrupt cooperation between oncogenic KRAS and mutant p53 to mitigate metastasis.
▲这一研究的负责人,MD安德森癌症中心的Michael Kim博士(图片来源:CREDIT: MD ANDERSON CANCER CENTER)
参考资料:
[1] Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis. Retrieved April 20, 2021, from https://www.eurekalert.org/pub_releases/2021-04/uotm-mka040721.php
[2] AACR: MD Anderson team uncovers new target for blocking mutant KRAS and p53 in pancreatic cancer. Retrieved April 20, 2021, from https://www.fiercebiotech.com/research/aacr-md-anderson-team-uncovers-new-target-for-blocking-mutant-kras-and-p53-pancreatic
[3] Kim et al., (2021). Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discovery, DOI: 10.1158/2159-8290.CD-20-1228